News | December 03, 2006

Docs Should Alert ICD/Pacemaker Patients About Magnets

Magnets may interfere with the operation of pacemakers and implantable cardioverter defibrillators (ICDs), according to a study published in the December 2006 edition of “Heart Rhythm.”

A release from the Heart Rhythm Society reports that researchers found that while common magnets for home and office use with low magnetic strength posed little risk, stronger magnets made from neodymium-iron-boron (NdFeB) may cause interference with cardiac devices and pose potential hazards to patients. NdFeB magnets are increasingly being used in homes and office products, toys, jewelry and even clothing.

“Physicians should caution patients about the risks associated with these magnets,” says Thomas Wolber, a cardiologist at the University Hospital of Zurich in Switzerland and lead author of the study. “We also recommend that the packaging include information on the potential risks that may be associated with these types of magnets.”

Two spherical magnets of eight and 10 millimeters in diameter and one necklace made of 45 spherical magnets were tested on 70 patients, 41 with pacemakers and 29 with ICDs. Magnetic interference was observed in all patients. The cardiac devices resumed normal function after the magnets were removed.

“This study is timely and important to attract the attention of both the public and the medical profession about the potentially serious health consequences of magnets used in decoration products... for an ICD patient, the magnet interference can be fatal,” writes Huagui Li, M.D., a cardiologist at the Minnesota Heart Clinic in Edina, MN, in an accompanying “Heart Rhythm” editorial.

Dr. Li concludes that manufacturers who use magnets should be required to put warning labels on their products for optimal patient safety.

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init